Bausch Health Companies Inc. filings document regulatory disclosures for a global diversified pharmaceutical company incorporated in British Columbia. The record includes Form 8-K reports for quarterly and annual operating results, Regulation FD updates, clinical-program disclosures, material agreements, debt exchanges and credit-agreement refinancing involving Bausch Health and its subsidiaries, including Bausch + Lomb.
Proxy materials describe annual meeting matters, director elections, auditor approval, executive compensation votes and governance procedures. Other current reports address compensatory arrangements, including performance share unit settlement terms, and capital-structure disclosures tied to senior secured notes, guarantees, collateral arrangements and refinancing transactions.
Bausch Health (NYSE:BHC) disclosed that subsidiary Bausch + Lomb completed a €675 million senior secured floating-rate notes issue due 2031 and entered a Third Amendment to its credit agreement, adding a $2.325 billion term loan maturing 2031 and upsizing its revolver to $800 million maturing 2030.
Proceeds refinanced all term A/B loans and repaid the prior revolver, shifting the nearest debt wall from 2027 to 2031. The notes price at 3-month EURIBOR (0% floor) + 3.875%; the term loans bear SOFR + 4.25% (base-rate option + 3.25%). Covenants include a first-lien net leverage cap of 5.75×, stepping down to 5.50×, plus customary limits on liens, investments and asset sales. Optional redemption is at par after 30 Jun 2026; change-of-control put at 101%.
- Debt issued: €675 m notes & $2.325 b term loan
- Liquidity: new $800 m revolver
- Use of proceeds: refinance 2027 debt & repay revolver